Legend Biotech Corp ADR LEGN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Stocks to Watch: Smith & Wesson, Logistic Properties of the Americas, Legend Biotech
-
Legend Biotech ADSs Fall After Company Announces Public Offering
-
Legend Biotech ADRs Climb on Preliminary Study Results for Non-Hodgkin Lymphoma Treatment
-
Legend Biotech Down Over 14%, on Track for Record Low Close — Data Talk
-
Legend Biotech Taps AstraZeneca Executive for CFO
-
Legend Biotech on Track for Record Losing Streak — Data Talk
Trading Information
- Previous Close Price
- $22.71
- Day Range
- $22.23–23.13
- 52-Week Range
- $16.24–45.30
- Bid/Ask
- $22.23 / $23.00
- Shares Outstanding
- 193.44M
- Market Cap
- $4.31B
- Volume/Avg
- 2M / 3M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 3.61
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 3,100
- Website
- https://www.legendbiotech.com
Valuation
|
Metric
|
LEGN
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 4.64 |
Price/Sales | 3.61 |
Price/Cash Flow | 309.88 |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
LEGN
|
|---|---|
Quick Ratio | 2.01 |
Current Ratio | 2.13 |
Interest Coverage | −11.45 |
Quick Ratio
LEGN
Profitability
|
Metric
|
LEGN
|
|---|---|
Return on Assets (Normalized) | −1.00% |
Return on Equity (Normalized) | −1.80% |
Return on Invested Capital (Normalized) | −2.16% |
Return on Assets
LEGN
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|YR<n?@ | LOCK|^?&c | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|%nvZzC& | LOCK|&m!^ | $71B | |||
| argenx SE ADR
ARGX
| LOCK|WTk#J@ | LOCK|&wB | $54B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|#qlSq>v | LOCK|>N | $36B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|x$#?J<& | LOCK|?^Xj | $36B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|&b!?Yq^ | LOCK|%qfdN | $26B | |||
| Moderna Inc
MRNA
| LOCK|%Pr!%lM | LOCK|#v | $25B | |||
| Incyte Corp
INCY
| LOCK|<!>QKsl | LOCK|q% | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|#hFG^d | LOCK|f$g | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|$nxG&G^ | LOCK|k> | $16B |
United States